# A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma

> **NCT00762255** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 19 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Vorinostat
- **DRUG:** Bevacizumab
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT00762255
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2013-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00762255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00762255, "A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00762255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*